Inspiration for COVID-19 Treatment: Network Analysis and Experimental Validation of Baicalin for Cytokine Storm

Jia You, Huawei Li, Peng Fan, Xi Yang, Yuanfeng Wei, Lingnan Zheng, Zhaojun Li, Yi ChengFrontiers in Pharmacology 2022 · DOI

TL;DR

This study investigates the potential of baicalin, a traditional Chinese medicine compound, to treat cytokine storms (CS), a dangerous hyperinflammatory response implicated in severe COVID-19. Using network analysis and molecular docking, researchers identified key targets and pathways, finding that baicalin strongly interacts with TNF-α and experimentally validated its ability to inhibit TNF-α production, suggesting baicalin as a promising therapeutic agent for CS.

What Problem Does This Paper Address?

Cytokine storms (CS) are a critical factor in the severity and mortality of diseases like COVID-19, characterized by an overactive immune response that damages multiple organs. While current treatments like cytokine inhibitors exist, they can also suppress beneficial immune functions and increase the risk of reinfection. This creates an urgent need for novel, effective therapeutic strategies that can modulate the immune response without compromising overall immunity. Baicalin, a compound derived from Scutellaria baicalensis, has known anti-inflammatory and antiviral properties, but its specific mechanisms for combating CS, particularly in the context of COVID-19, were not fully understood. This paper aims to bridge that gap by identifying baicalin's molecular targets and pathways involved in CS and experimentally validating its efficacy.

Methods

The researchers employed a multi-pronged approach:

  • Target Identification: They gathered potential molecular targets for baicalin from the Swiss Target Prediction database and identified genes associated with cytokine storms from public databases like GeneCards, OMIM, and PharmGKB.
  • Network Analysis: They constructed a protein-protein interaction (PPI) network of the overlapping targets using Cytoscape 9.0. Network topology analysis was performed using CytoNCA to identify "core targets" – genes with significant connections and influence within the network.
  • Molecular Docking: To predict the binding affinity and mode between baicalin and the identified core targets, they used the SURFLEX-Dock software. This technique assesses how well a drug molecule (baicalin) fits into the active site of a target protein.
  • Experimental Validation:
    • In vitro: They used MH-S cells to create a CS model and tested baicalin's ability to inhibit TNF-α secretion. Cell viability was assessed to ensure baicalin wasn't directly toxic at the tested concentrations.
  • In vivo: They induced CS in mice using lipopolysaccharide (LPS) and administered baicalin. They then measured TNF-α levels in bronchoalveolar lavage fluid (BALF) and assessed inflammatory cell exudation.
  • Functional Enrichment Analysis: Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses were performed using R language to understand the biological processes and signaling pathways associated with the identified targets.

Datasets

The study utilized publicly available databases for target identification:

  • Swiss Target Prediction Database: For potential targets of baicalin.
  • PubChem: For the 2D molecular structure and SMILES of baicalin.
  • GeneCards, OMIM, and PharmGKB: For genes associated with cytokine storms.

The study did not introduce new benchmark datasets.

Key Insights and Ideas

  • Baicalin as a Multi-Target Agent: The study revealed that baicalin doesn't just target one molecule but interacts with a network of 86 genes common to both baicalin's known targets and CS. This suggests a complex, multi-faceted therapeutic approach.
  • TNF-α as a Central Player: Molecular docking strongly indicated that baicalin binds most effectively to TNF-α, a key pro-inflammatory cytokine. This was a crucial insight, as TNF-α is a well-established driver of CS.
  • Experimental Confirmation of TNF-α Inhibition: The in vitro and in vivo experiments provided robust evidence that baicalin can indeed suppress elevated TNF-α levels, directly validating the molecular docking findings.
  • Key Pathways Identified: The GO and KEGG analyses pointed towards the TNF signaling pathway and the IL-17 signaling pathway as crucial routes through which baicalin exerts its anti-CS effects. This provides a deeper understanding of the molecular mechanisms.

Key Results

  • 86 Overlapping Targets: A total of 86 genes were identified as common targets for baicalin and CS.
  • Core Targets: Eight core targets were identified from the PPI network: MAPK14, IL2, FGF2, CASP3, PTGS2, PIK3CA, EGFR, and TNF.
  • Strongest Binding to TNF: Molecular docking showed baicalin had the highest docking score (9.24) and a C Score of 4.0 with TNF, indicating a strong and stable interaction.
  • Inhibition of TNF-α:
    • In vitro: Baicalin significantly inhibited TNF-α secretion in LPS-activated macrophages.
  • In vivo: Baicalin administration reduced TNF-α levels in the BALF of mice with LPS-induced CS.
  • Key Pathways: TNF signaling and IL-17 signaling pathways were identified as potentially important for baicalin's anti-CS action.

Limitations and Future Work

  • Incomplete Mechanism: The authors acknowledge that the specific mechanism of action of baicalin remains incomplete and requires further experimental exploration.
  • Further Experiments: They suggest that future studies should delve deeper into the precise molecular interactions and downstream effects of baicalin.
  • Broader Applications: While focused on COVID-19-related CS, the study's findings could provide a theoretical basis and research direction for treating cytokine storm syndromes induced by a broader range of infections and pandemic diseases.

Summary updated

Abstract

<b>Background:</b> Cytokine storm (CS) is a systemic inflammatory syndrome and a major cause of multi-organ failure and even death in COVID-19 patients. With the increasing number of COVID-19 patients, there is an urgent need to develop effective therapeutic strategies for CS. Baicalin is an anti-inflammatory and antiviral traditional Chinese medicine. In the present study, we aimed to evaluate the therapeutic mechanism of baicalin against CS through network analysis and experimental validation, and to detect key targets of CS that may bind closely to baicalin through molecular docking. <b>Method:</b> Access to potential targets of baicalin and CS in public databases. We constructed the protein-protein interaction (PPI) network of baicalin and CS by Cytoscape 9.0 software and performed network topology analysis of the potential targets. Then, the hub target was identified by molecular docking technique and validated in the CS model. Finally, GO and KEGG pathway functional enrichment analysis of common targets were confirmed using R language, and the location of overlapping targets in key pathways was queried via KEGG Mapper. <b>Result:</b> A total of 86 overlapping targets of baicalin and CS were identified, among which MAPK14, IL2, FGF2, CASP3, PTGS2, PIK3CA, EGFR, and TNF were the core targets. Moreover, it was found that baicalin bound most closely to TNF through molecular docking, and demonstrated that baicalin can effectively inhibit the elevation of TNF-α <i>in vitro</i> and <i>in vivo</i>. Furthermore, bioenrichment analysis revealed that the TNF signaling pathway and IL-17 signaling pathway may be potential key pathways for baicalin to treat CS. <b>Conclusion:</b> Based on this study, baicalin was identified as a potential drug for the alleviation of CS, and the possible key targets and pathways of baicalin for the treatment of CS were elucidated to reveal the main pharmacological mechanisms.
BibTeX
@inproceedings{you2022inspiration,
  author = {Jia You and Huawei Li and Peng Fan and Xi Yang and Yuanfeng Wei and Lingnan Zheng and Zhaojun Li and Yi Cheng},
  title = {{Inspiration for COVID-19 Treatment: Network Analysis and Experimental Validation of Baicalin for Cytokine Storm}},
  booktitle = {Frontiers in Pharmacology},
  year = {2022},
  doi = {10.3389/fphar.2022.853496},
}
Figure